{
  "$type": "site.standard.document",
  "bskyPostRef": {
    "cid": "bafyreidl4ghfilxcwdjpavqvf7hzydi2q3gxst4kwsnlbdyc6imdpleyjy",
    "uri": "at://did:plc:wwyqal4cnqhuwyacdj7rqq3n/app.bsky.feed.post/3mla5qh7blfs2"
  },
  "path": "/t/rms-semiparametric-ordinal-longitudinal-model/4819?page=6#post_118",
  "publishedAt": "2026-05-06T11:19:00.000Z",
  "site": "https://discourse.datamethods.org",
  "textContent": "I think you reanalyzed ACTT-1 in Rhode et al, ACTT-2 is Baricitinib (JAK-Inhibitor). But patient populations does seem quite similar, I don’t have access to ACTT-1 unfortunately. I shall have a look at time to recovery in ACTT-2 and how it depends on the baseline state.",
  "title": "RMS Semiparametric Ordinal Longitudinal Model"
}